De novo metastatic hormone-sensitive prostate cancer usually has a dismal prognosis, which has slightly improved in recent years thanks to the introduction of new hormonal agents and …

Sep 9, 2024 · Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of …

Apr 11, 2025 · Over the past decade, the treatment landscape for de novo metastatic hormone-sensitive prostate cancer (mHSPC) has undergone a remarkable transformation. Treatment …

May 23, 2023 · The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for …

Jul 16, 2025 · The treatment of metastatic hormone-sensitive prostate cancer has evolved rapidly, with the emergence of doublet and triplet therapies transforming outcomes. However, these …

QuestionHow has treatment for and survival of metastatic hormone-sensitive prostate cancer (mHSPC) changed over time? FindingsIn a cross-sectional study of 6216 veterans with de …

Jan 20, 2025 · De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic …

Mar 20, 2023 · Annually, >1.2 million new cases of prostate cancer are diagnosed and global prostate cancer-related deaths exceed 350 000 per annum, making it one of the leading …

Jul 7, 2025 · The treatment of metastatic hormone-sensitive prostate cancer has changed substantially over the past decade, with androgen deprivation therapy (ADT) combined with …

H&O Is it more common for metastatic hormone-sensitive prostate cancer (mHSPC) to present de novo or as relapsed disease? KC The overall rate of mortality from prostate cancer is …